Recombinant Hemagglutinin Antigen Composition for Broad Influenza Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines for influenza virus are less effective due to the diversity of hemagglutinin and neuraminidase proteins, leading to mismatches between predicted and actual epidemic strains, and there is a need for universal vaccines that can target various subtypes and variants safely and effectively.
Innovation Solution
Development of an antigen composition containing recombinant hemagglutinin monomeric proteins with specific mutations and disulfide bond mutations, along with fusion proteins using scaffold fragments, to enhance immune response and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional influenza vaccines are prepared using predicted epidemic strains, then vaccine production is feasible and standardized, but vaccine effectiveness decreases when actual epidemic strains mismatch the predicted strains
Solution Approach 1:
The patent applies universality by designing a chimeric hemagglutinin protein that combines conserved regions from multiple influenza virus subtypes (H1, H3, and B virus stem regions) into a single antigen structure. This allows the vaccine to induce cross-reactive antibodies that recognize multiple virus subtypes, transforming a subtype-specific vaccine into a universal vaccine that functions against diverse influenza strains without requiring annual reformulation
2Adaptability or versatility
If vaccine antigens are designed to target highly conserved regions of viral proteins, then cross-subtype immunity is improved, but the complexity of antigen design and production increases
Solution Approach 1:
The patent applies segmentation by dividing the chimeric hemagglutinin protein into distinct functional domains: a conserved stem region from H1, a conserved stem region from H3, and a conserved stem region from B virus, each connected by flexible linkers. This modular segmentation allows for systematic construction of the antigen, enabling precise control over which conserved regions are included and how they are arranged, thereby managing design complexity while achieving broad immunity
Solution Approach 2:
The patent applies composite materials by creating a chimeric protein that fuses amino acid sequences from three different viral sources (H1, H3, and B virus) into a single hybrid antigen. This composite structure combines the advantageous conserved epitopes from each source, producing an antigen that elicits cross-reactive immune responses against multiple influenza subtypes while maintaining structural integrity and immunogenicity
3Object-affected harmful factors
If monomeric hemagglutinin proteins are used as vaccine antigens, then safety and recyclability are improved, but immune response induction may be reduced compared to viral vectors
Solution Approach 1:
The patent applies composite materials by incorporating the chimeric hemagglutinin monomeric protein into a liposome formulation that includes immunostimulatory components. This composite vaccine structure enhances the immunogenicity of the monomeric protein antigen, compensating for its lower inherent immunogenicity compared to viral vectors while maintaining the safety advantages of protein-based antigens. The liposome carrier acts as an adjuvant system that boosts immune response without requiring replication-capable viral components
Data Source
AI summary
The present invention relates to an antigen composition for preventing or treating viral infectious diseases, comprising, as an active ingredient, a multiple variant protein of a recombinant hemagglutinin monomeric protein in an influenza virus. In addition, the present invention relates to an antigen composition for preventing or treating viral infectious diseases, comprising a scaffold-based fusion protein. The antigen composition for preventing or treating viral infectious diseases, according to the present invention, has an outstanding preventive effect of inhibiting the proliferation and replication of viruses having various mutations, and is recyclable and safe by means of using a recombinant protein, and thus can be widely used in various industrial fields, such as the medicine and life science fields.